Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes. - Wikidata - awgldk - TriplyDB

Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes.

Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes.

http://www.wikidata.org/entity/Q33873025

about

Aspirin for primary prevention of cardiovascular disease in diabetes mellitus Risk threshold for starting low dose aspirin in pregnancy to prevent preeclampsia: an opportunity at a low cost.Quality of Diabetes Care in Germany Improved from 2000 to 2007 to 2014, but Improvements Diminished since 2007. Evidence from the Population-Based KORA Studies.Screening for type 2 diabetes and dysglycemia.Utility estimates for patients with Type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: a systematic review.Evaluation of aspirin use in patients with diabetes receiving care in community health.Cost effectiveness of full coverage of the medical management of smoking cessation in France.

P2860

Q35132896-038FC110-6DDC-4254-A76B-BE2303A45B1E Q35196095-E8435036-9872-4CB5-AEE9-02B62139C9A5 Q36165379-FF4E03C1-67C5-4FFC-84EB-C7A3C5802DA3 Q37882225-7C8C2FAE-DC4F-4533-BE7E-89AC685E084D Q38306101-00383EBE-41C5-43B7-ABD8-ABC7C2E8225D Q51045941-9A84DA4F-FA6F-4018-AA49-6FD22307E5CB Q51199648-3F672C14-1E42-40D8-AAAB-5A2DF1C1D001

P2860

Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes.

http://www.wikidata.org/entity/Q33873025

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes.

@ast

Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes.

@en

type

label

Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes.

@ast

Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes.

@en

prefLabel

Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes.

@ast

Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes.

@en

P1433

Q33873025-6422AD32-685F-4A2D-9189-13BD18A2286B

P1476

Q33873025-5055E46E-12C2-4AEB-9E63-987E9625DA03

P2093

Q33873025-413BD085-9A29-4EC5-9E48-A742A3CF07E8

Q33873025-583E786C-4F35-4FD4-B106-1854EEECF656

Q33873025-79C24002-1B82-4A84-98F0-E124C1E6C28A

Q33873025-E1448A32-529F-43D4-8E37-984F84A21F29

P2860

Q33873025-0C70B8DF-C925-46A2-8764-5DCEDA0A73D1

Q33873025-184D9278-AC93-4B43-BCC8-CE423469DE1D

Q33873025-1AE9152B-7AD6-4CC2-872A-5300838B759A

Q33873025-2E6B7EAA-4860-48B3-9824-BB89D1163998

Q33873025-32E555E9-F5A8-4BA7-A312-B8114748ACEE

Q33873025-33FA533F-4114-46EB-A20F-41A685211D45

Q33873025-35C8DA4D-546C-4867-A29C-BA8883B31A31

Q33873025-470D0089-197F-41FE-8507-A348C23069D2

Q33873025-51B95C46-5CE8-40FC-9D12-20F1E7B220FD

Q33873025-52DEBB90-F91F-4222-8A36-AFBC72D3D979

P304

Q33873025-DB1DA61C-C642-424D-B8CB-32ADADFF691D

P31

Q33873025-D8A89ADC-AAD3-4FED-A4AF-EADED59392BB

P356

Q33873025-C7BDE252-874A-4D59-8A78-167A8B99F63E

P407

Q33873025-60CCC146-0220-4C98-ABE7-DEC807AA38CE

P433

Q33873025-C6B43989-7D3F-4842-923A-5B3922DDC73E

P478

Q33873025-03B6C868-ECC9-4040-8AB2-ACBF6B729342

P577

Q33873025-D1B09F9C-58C8-45D3-BBCC-F1650E3522D2

P5875

Q33873025-7FBE9757-88C0-4C6E-9003-3B99EB7B19C4

P698

Q33873025-A0CE5367-1478-44FB-A161-B0F1E031BBD2

P921

Q33873025-5898AA7A-C813-46FC-A240-5D07E0464910

Q33873025-7C3FAF54-8499-4871-8D30-77034598606F

P932

Q33873025-A172F362-2062-4134-B9AC-BF0B6F77355F

P356

P1433

P1476

Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes.

@en

P2093

Lawrence E Barker

http://www.w3.org/2001/XMLSchema#string

Ping Zhang

http://www.w3.org/2001/XMLSchema#string

Rui Li

http://www.w3.org/2001/XMLSchema#string

Thomas J Hoerger

http://www.w3.org/2001/XMLSchema#string

P2860

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

Aspirin for the primary prevention of cardiovascular events: recommendation and rationale

Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis

Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002

Changing aspirin use in patients with Type 2 diabetes in the UKPDS

Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials.

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.

P304

1193-1199

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC09-1888

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42440752

http://www.w3.org/2001/XMLSchema#string

P698

20332350

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

2875422

http://www.w3.org/2001/XMLSchema#string